Supplementary Figure 2.

Effect of timing of anti-GM-CSF treatment on arthritis development. (a) Mice treated on day 21 (n = 17, anti-GM-CSF) or days 21 and 23 (n = 20, anti-GM-CSF; n = 20, isotype control). ^* Days 21 and 23 treatment, anti-GM-CSF treated versus isotype control treated mice (day 40) (P = 0.044; Mann-Whitney test). (b) Mice treated at the time of primary immunization (day 0) only (n = 10, anti-GM-CSF; n = 9, isotype control). (c) Mice treated at the time of primary immunization (day 0) then weekly until day 21 (n = 10, anti-GM-CSF; n = 10, isotype control). For all treatments, 300 ?g anti-GM-CSF or isotype control was used. Results are expressed as the mean ? SEM. GM-CSF, Granulocyte macrophage-colony stimulating factor.